AB1191 would create a new state statute, section 299.485, to phase out the sale and distribution of products containing intentionally added PFAS, a class of fluorinated chemicals often used for stain resistance, water resistance, and other performance features. Beginning January 1, 2032, the bill would prohibit PFAS in a list of specified consumer products, including food packaging, carpets and rugs, cleaning products, cookware, cosmetics, dental floss, fabric treatments, juvenile products, menstruation products, textile furnishings, ski wax, and upholstered furniture. It would also allow the Department of Natural Resources (DNR) to expand the list by rule and to identify products for which PFAS use is considered unavoidable.
The bill would then extend the prohibition much more broadly on January 1, 2038, barring the sale or distribution of any product containing intentionally added PFAS unless the DNR has determined the use is unavoidable. Manufacturers would have to submit product and PFAS-use information to the DNR, update that information for new products or significant changes, and provide testing results if the department has reason to believe a product contains intentionally added PFAS. The bill also defines several key terms, including PFAS, food packaging, juvenile products, textile furnishings, and unavoidable use, and includes exemptions for federally preempted products, firefighting foam, used products, and certain medical devices or medical applications.
The bill would significantly affect product manufacturing, retail sales, and regulatory oversight in Wisconsin by creating a statewide restriction on PFAS-containing consumer goods and giving DNR new rulemaking and enforcement authority. It would also establish a civil forfeiture of $100 per violating product per day, creating a compliance incentive for manufacturers, distributors, and sellers. In practical terms, the measure would require affected businesses to reformulate products, track chemical content, and document compliance over time.
Overall sentiment in the available record appears limited but generally policy-driven rather than contentious in the materials provided. The bill was introduced with bipartisan cosponsorship and referred to the Committee on Environment, suggesting at least some legislative interest in PFAS reduction and consumer/environmental protection. However, the bill ultimately failed to pass pursuant to Senate Joint Resolution 1, indicating it did not advance through the legislative process.
The main points of contention likely center on the breadth of the PFAS ban, the long-term statewide prohibition on all intentionally added PFAS, the compliance burden on manufacturers, and the scope of DNR authority to identify additional restricted products and determine unavoidable uses. Exemptions for medical products and federally regulated items may have been intended to address some concerns, but the bill still would have imposed a broad regulatory framework on a wide range of consumer goods and industries.
AB1191 would create s. 299.485 and add a new regulatory regime governing PFAS in consumer products. It would authorize DNR to collect manufacturer disclosures, require testing, adopt rules identifying additional banned products and unavoidable uses, and enforce the ban through civil forfeitures. The bill would affect manufacturers, distributors, retailers, and consumers by restricting the sale of specified PFAS-containing products starting in 2032 and nearly all intentionally added PFAS products by 2038, subject to exemptions.
The available context suggests a generally supportive environmental and public-health rationale, with bipartisan sponsorship and no recorded committee debate or roll-call votes in the materials provided. At the same time, the bill’s failure to pass indicates it did not achieve final legislative approval. The absence of transcript discussion limits the ability to identify detailed support or opposition, but the measure appears to have been treated as a policy proposal aimed at reducing PFAS exposure rather than as a partisan flashpoint.
Likely areas of disagreement include whether the state should impose a broad phaseout of intentionally added PFAS, how quickly industry could comply, and whether DNR should have discretion to expand the list of restricted products by rule. Manufacturers and affected retailers would likely be concerned about testing, reporting, reformulation costs, and liability for daily forfeitures, while environmental and public-health advocates would likely favor the bill’s broad restrictions and long-term phaseout. Exemptions for medical uses, firefighting foam, used products, and federally preempted products appear designed to narrow the bill, but they also highlight the tension between environmental goals and practical or federally regulated uses.